November 13, 2007 — Arterial Remodeling Technologies (ART) will receive $7.8 million from investors to pursue CE Mark ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
November 4, 2007 – A patient care program in North Carolina shortened the time it took to treat heart attack patients ...
November 05, 2007
November 4, 2007 - Itamar Medical announced that four presentations at AHA, including one from the Framingham Heart ...
November 05, 2007November 5, 2007 - A pooled analysis of the E-SIRIUS and C-SIRIUS trials, called New SIRIUS, found that the CYPHER ...
November 04, 2007November 5, 2007 – Boston Scientific Corp. highlighted at the American Heart Association conference its new Stentplus ...
November 04, 2007November 4, 2007 – The antiplatelet drug prasugrel offered greater benefit than current, standard therapy for patients ...
November 03, 2007November 4, 2007 – A specific way of dosing eptifibatide appears equally effective as giving abciximab as an adjunct to ...
November 03, 2007November 4, 2007 – Drug-eluting stents to open blocked coronary arteries caused no more risks for death or heart ...
November 03, 2007October 23, 2007 – Boston Scientific Corp. announced five-year and final follow-up data from its TAXUS IV clinical trial ...
October 28, 2007October 24, 2007 - Presented at the TCT 2007 meeting, a pooled analysis of safety data from Medtronic’s ENDEAVOR ...
October 24, 2007OCTOBER 23, 2007 – Abbott’s fully bioabsorbable drug eluting stent platform for the treatment of coronary artery disease ...
October 22, 2007October 23, 2007 - ENDEAVOR IV reached its primary endpoint of target vessel failure non-inferiority when compared to ...
October 22, 2007October 23, 2007 – Patients who received the CYPHER Sirolimus-eluting coronary stent had a lower risk of stent ...
October 22, 2007October 23, 2007 – After 12 months of the SPIRIT III trial, there were significantly fewer major adverse cardiac ...
October 22, 2007October 22, 2007 - Implantation of the CYPHER Sirolimus-eluting Coronary Stent by Cordis Corp. used to treat completely ...
October 21, 2007© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now